Ironwood Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference
30 Mai 2024 - 10:01PM
Business Wire
Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) today announced
that Sravan Emany, Chief Financial Officer, will participate in a
fireside chat at the Jefferies Global Healthcare Conference on
Thursday, June 6, 2024 at 9:00 a.m. ET at the Marriott Marquis in
New York City.
A live webcast of Ironwood’s fireside chat will be accessible
through the Investors section of the company’s website at
www.ironwoodpharma.com. To access the webcast, please log on to the
Ironwood website approximately 15 minutes prior to the start time
to ensure adequate time for any software downloads that may be
required. A replay of the webcast will be available on Ironwood’s
website for 1 year following the conference.
About Ironwood Pharmaceuticals
Ironwood Pharmaceuticals (Nasdaq: IRWD), an S&P SmallCap
600® company, is a leading gastrointestinal (GI) healthcare company
on a mission to advance the treatment of GI diseases and redefine
the standard of care for GI patients. We are pioneers in the
development of LINZESS® (linaclotide), the U.S. branded
prescription market leader for adults with irritable bowel syndrome
with constipation (IBS-C) or chronic idiopathic constipation (CIC).
LINZESS is also approved for the treatment of functional
constipation in pediatric patients ages 6-17 years-old. Ironwood is
also advancing apraglutide, a next-generation, long-acting
synthetic GLP-2 analog being developed for rare gastrointestinal
diseases, including short bowel syndrome with intestinal failure
(SBS-IF), as well as several earlier stage assets. Building upon
our history of GI innovation, we keep patients at the heart of our
R&D and commercialization efforts to reduce the burden of GI
diseases and address significant unmet needs.
Founded in 1998, Ironwood Pharmaceuticals is headquartered in
Boston, Massachusetts, with a site in Basel, Switzerland.
We routinely post information that may be important to investors
on our website at www.ironwoodpharma.com. In addition, follow us on
Twitter and on LinkedIn.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240530953466/en/
Investors:
Greg Martini, 617-374-5230 gmartini@ironwoodpharma.com
Matt Roache, 617-621-8395 mroache@ironwoodpharma.com
Media:
Beth Calitri, 978-417-2031 bcalitri@ironwoodpharma.com
Ironwood Pharmaceuticals (NASDAQ:IRWD)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024
Ironwood Pharmaceuticals (NASDAQ:IRWD)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024
